Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder in Pulmonary Arterial Hypertension
NCT05649748Phase 3Active, not recruiting
- Sponsor
- Insmed Incorporated
- Start
- Mar 2023
- Primary completion
- Dec 2026
- Modality
- Inhalation Devices, Prodrugs/Conditional Activator Small Molecules
- Countries
- 15
01
Overview
Phase 3, open-label, single-arm trial of treprostinil palmitil in pulmonary arterial hypertension (PAH), sponsored by Insmed Incorporated. Primary endpoint: Treatment Emergent Adverse Events at 26 months. Started Mar 2023; status: active, not recruiting.
02
Drugs
treprostinil palmitil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT05649748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05649748.